Loading…
Genomic aberrations in non- small cell lung cancer and their impact on treatment outcome
The therapeutic options of nonsmall cell lung cancer (NSCLC) therapy has been changed since the first discovery of activating epidermal growth factor receptor (EGFR) mutations and the development of specific EGFR tyrosine kinase inhibitors, which resulted in the evolution of "personalized medic...
Saved in:
| Published in: | Journal of cancer research and therapeutics 2017-01, Vol.13 (1), p.9-15 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c474t-4c5e4a38a6f6ec3f2a2f437aede8e43e80570be55c8436bfda7a82925a90aaa3 |
|---|---|
| cites | |
| container_end_page | 15 |
| container_issue | 1 |
| container_start_page | 9 |
| container_title | Journal of cancer research and therapeutics |
| container_volume | 13 |
| creator | Mohammed, Amrallah A El-Tanni, Hani Alsakkaf, Mohammed A Mirza, Ahmad A Atiah, Tariq Al-Malki Atiah, Arwa Al-Malki |
| description | The therapeutic options of nonsmall cell lung cancer (NSCLC) therapy has been changed since the first discovery of activating epidermal growth factor receptor (EGFR) mutations and the development of specific EGFR tyrosine kinase inhibitors, which resulted in the evolution of "personalized medicine." There are a considerable number of genomic aberrations in NSCLC serving as potential predictive biomarkers and drug targets and still more. We summarized the molecular pathways, potential targets, and possible impact on disease outcome in NSCLC. |
| doi_str_mv | 10.4103/0973-1482.180605 |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1899406209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A492865969</galeid><sourcerecordid>A492865969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-4c5e4a38a6f6ec3f2a2f437aede8e43e80570be55c8436bfda7a82925a90aaa3</originalsourceid><addsrcrecordid>eNptkc9rHCEcxSU0NJu0956K0Esvs_HnjB5DaNNCoJccepPvOt_ZGGZ0qzOH_vd12DSlYREU9fMeTx8hHzjbKs7kNbOdbLgyYssNa5k-IxturWkUl-YN2bxcX5DLUp4Y050Q5i25EEYzY0S7IT_vMKYpeAo7zBnmkGKhIdKYYkPLBONIPdZpXOKeeogeM4XY0_kRQ6ZhOoCfaYp0zgjzhLFultmnCd-R8wHGgu-f1yvy8PXLw-235v7H3ffbm_vGq07NjfIaFUgD7dCil4MAMSjZAfZoUEk0NTPbodbeKNnuhh46MMIKDZYBgLwin4-2h5x-LVhmN4WyJoaIaSmOG2sVawWzFf30Cn1KS441nOOWS8W0YeIftYcRXYhDmjP41dTdKCtMq227ejUnqD1GzDCmiEOox__x2xN8HT3Wzz8pYEeBz6mUjIM75DBB_u04c2v3bi3XreW6Y_dV8vH5fctuwv5F8Lds-QfYpacy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1913405802</pqid></control><display><type>article</type><title>Genomic aberrations in non- small cell lung cancer and their impact on treatment outcome</title><source>Publicly Available Content (ProQuest)</source><source>IngentaConnect Journals</source><creator>Mohammed, Amrallah A ; El-Tanni, Hani ; Alsakkaf, Mohammed A ; Mirza, Ahmad A ; Atiah, Tariq Al-Malki ; Atiah, Arwa Al-Malki</creator><creatorcontrib>Mohammed, Amrallah A ; El-Tanni, Hani ; Alsakkaf, Mohammed A ; Mirza, Ahmad A ; Atiah, Tariq Al-Malki ; Atiah, Arwa Al-Malki</creatorcontrib><description>The therapeutic options of nonsmall cell lung cancer (NSCLC) therapy has been changed since the first discovery of activating epidermal growth factor receptor (EGFR) mutations and the development of specific EGFR tyrosine kinase inhibitors, which resulted in the evolution of "personalized medicine." There are a considerable number of genomic aberrations in NSCLC serving as potential predictive biomarkers and drug targets and still more. We summarized the molecular pathways, potential targets, and possible impact on disease outcome in NSCLC.</description><identifier>ISSN: 0973-1482</identifier><identifier>EISSN: 1998-4138</identifier><identifier>DOI: 10.4103/0973-1482.180605</identifier><identifier>PMID: 28508826</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Biomarkers, Tumor - genetics ; Cancer ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Care and treatment ; Cell division ; Cell growth ; Chemotherapy ; Clinical trials ; Development and progression ; Epidermal growth factor ; FDA approval ; Genes ; Genetic aspects ; Genome, Human - drug effects ; Genome, Human - genetics ; Genomes ; Genomics ; Humans ; Kinases ; Lung cancer ; Lung cancer, Non-small cell ; Medical prognosis ; Medical research ; Medicine ; Metastasis ; Molecular Targeted Therapy ; Mutation ; Oncology ; Patient outcomes ; Precision Medicine ; Receptor, Epidermal Growth Factor - antagonists & inhibitors ; Receptor, Epidermal Growth Factor - genetics ; Response rates ; Signal Transduction - drug effects ; Treatment Outcome</subject><ispartof>Journal of cancer research and therapeutics, 2017-01, Vol.13 (1), p.9-15</ispartof><rights>COPYRIGHT 2017 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications & Media Pvt. Ltd. Jan/Mar 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-4c5e4a38a6f6ec3f2a2f437aede8e43e80570be55c8436bfda7a82925a90aaa3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1913405802?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,4023,25752,27922,27923,27924,37011,37012,44589</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28508826$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mohammed, Amrallah A</creatorcontrib><creatorcontrib>El-Tanni, Hani</creatorcontrib><creatorcontrib>Alsakkaf, Mohammed A</creatorcontrib><creatorcontrib>Mirza, Ahmad A</creatorcontrib><creatorcontrib>Atiah, Tariq Al-Malki</creatorcontrib><creatorcontrib>Atiah, Arwa Al-Malki</creatorcontrib><title>Genomic aberrations in non- small cell lung cancer and their impact on treatment outcome</title><title>Journal of cancer research and therapeutics</title><addtitle>J Cancer Res Ther</addtitle><description>The therapeutic options of nonsmall cell lung cancer (NSCLC) therapy has been changed since the first discovery of activating epidermal growth factor receptor (EGFR) mutations and the development of specific EGFR tyrosine kinase inhibitors, which resulted in the evolution of "personalized medicine." There are a considerable number of genomic aberrations in NSCLC serving as potential predictive biomarkers and drug targets and still more. We summarized the molecular pathways, potential targets, and possible impact on disease outcome in NSCLC.</description><subject>Biomarkers, Tumor - genetics</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Care and treatment</subject><subject>Cell division</subject><subject>Cell growth</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Development and progression</subject><subject>Epidermal growth factor</subject><subject>FDA approval</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Genome, Human - drug effects</subject><subject>Genome, Human - genetics</subject><subject>Genomes</subject><subject>Genomics</subject><subject>Humans</subject><subject>Kinases</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Metastasis</subject><subject>Molecular Targeted Therapy</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Patient outcomes</subject><subject>Precision Medicine</subject><subject>Receptor, Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><subject>Response rates</subject><subject>Signal Transduction - drug effects</subject><subject>Treatment Outcome</subject><issn>0973-1482</issn><issn>1998-4138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkc9rHCEcxSU0NJu0956K0Esvs_HnjB5DaNNCoJccepPvOt_ZGGZ0qzOH_vd12DSlYREU9fMeTx8hHzjbKs7kNbOdbLgyYssNa5k-IxturWkUl-YN2bxcX5DLUp4Y050Q5i25EEYzY0S7IT_vMKYpeAo7zBnmkGKhIdKYYkPLBONIPdZpXOKeeogeM4XY0_kRQ6ZhOoCfaYp0zgjzhLFultmnCd-R8wHGgu-f1yvy8PXLw-235v7H3ffbm_vGq07NjfIaFUgD7dCil4MAMSjZAfZoUEk0NTPbodbeKNnuhh46MMIKDZYBgLwin4-2h5x-LVhmN4WyJoaIaSmOG2sVawWzFf30Cn1KS441nOOWS8W0YeIftYcRXYhDmjP41dTdKCtMq227ejUnqD1GzDCmiEOox__x2xN8HT3Wzz8pYEeBz6mUjIM75DBB_u04c2v3bi3XreW6Y_dV8vH5fctuwv5F8Lds-QfYpacy</recordid><startdate>201701</startdate><enddate>201701</enddate><creator>Mohammed, Amrallah A</creator><creator>El-Tanni, Hani</creator><creator>Alsakkaf, Mohammed A</creator><creator>Mirza, Ahmad A</creator><creator>Atiah, Tariq Al-Malki</creator><creator>Atiah, Arwa Al-Malki</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201701</creationdate><title>Genomic aberrations in non- small cell lung cancer and their impact on treatment outcome</title><author>Mohammed, Amrallah A ; El-Tanni, Hani ; Alsakkaf, Mohammed A ; Mirza, Ahmad A ; Atiah, Tariq Al-Malki ; Atiah, Arwa Al-Malki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-4c5e4a38a6f6ec3f2a2f437aede8e43e80570be55c8436bfda7a82925a90aaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Biomarkers, Tumor - genetics</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Care and treatment</topic><topic>Cell division</topic><topic>Cell growth</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Development and progression</topic><topic>Epidermal growth factor</topic><topic>FDA approval</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Genome, Human - drug effects</topic><topic>Genome, Human - genetics</topic><topic>Genomes</topic><topic>Genomics</topic><topic>Humans</topic><topic>Kinases</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Metastasis</topic><topic>Molecular Targeted Therapy</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Patient outcomes</topic><topic>Precision Medicine</topic><topic>Receptor, Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><topic>Response rates</topic><topic>Signal Transduction - drug effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mohammed, Amrallah A</creatorcontrib><creatorcontrib>El-Tanni, Hani</creatorcontrib><creatorcontrib>Alsakkaf, Mohammed A</creatorcontrib><creatorcontrib>Mirza, Ahmad A</creatorcontrib><creatorcontrib>Atiah, Tariq Al-Malki</creatorcontrib><creatorcontrib>Atiah, Arwa Al-Malki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohammed, Amrallah A</au><au>El-Tanni, Hani</au><au>Alsakkaf, Mohammed A</au><au>Mirza, Ahmad A</au><au>Atiah, Tariq Al-Malki</au><au>Atiah, Arwa Al-Malki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genomic aberrations in non- small cell lung cancer and their impact on treatment outcome</atitle><jtitle>Journal of cancer research and therapeutics</jtitle><addtitle>J Cancer Res Ther</addtitle><date>2017-01</date><risdate>2017</risdate><volume>13</volume><issue>1</issue><spage>9</spage><epage>15</epage><pages>9-15</pages><issn>0973-1482</issn><eissn>1998-4138</eissn><abstract>The therapeutic options of nonsmall cell lung cancer (NSCLC) therapy has been changed since the first discovery of activating epidermal growth factor receptor (EGFR) mutations and the development of specific EGFR tyrosine kinase inhibitors, which resulted in the evolution of "personalized medicine." There are a considerable number of genomic aberrations in NSCLC serving as potential predictive biomarkers and drug targets and still more. We summarized the molecular pathways, potential targets, and possible impact on disease outcome in NSCLC.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>28508826</pmid><doi>10.4103/0973-1482.180605</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0973-1482 |
| ispartof | Journal of cancer research and therapeutics, 2017-01, Vol.13 (1), p.9-15 |
| issn | 0973-1482 1998-4138 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1899406209 |
| source | Publicly Available Content (ProQuest); IngentaConnect Journals |
| subjects | Biomarkers, Tumor - genetics Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Care and treatment Cell division Cell growth Chemotherapy Clinical trials Development and progression Epidermal growth factor FDA approval Genes Genetic aspects Genome, Human - drug effects Genome, Human - genetics Genomes Genomics Humans Kinases Lung cancer Lung cancer, Non-small cell Medical prognosis Medical research Medicine Metastasis Molecular Targeted Therapy Mutation Oncology Patient outcomes Precision Medicine Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Response rates Signal Transduction - drug effects Treatment Outcome |
| title | Genomic aberrations in non- small cell lung cancer and their impact on treatment outcome |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A15%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genomic%20aberrations%20in%20non-%20small%20cell%20lung%20cancer%20and%20their%20impact%20on%20treatment%20outcome&rft.jtitle=Journal%20of%20cancer%20research%20and%20therapeutics&rft.au=Mohammed,%20Amrallah%20A&rft.date=2017-01&rft.volume=13&rft.issue=1&rft.spage=9&rft.epage=15&rft.pages=9-15&rft.issn=0973-1482&rft.eissn=1998-4138&rft_id=info:doi/10.4103/0973-1482.180605&rft_dat=%3Cgale_proqu%3EA492865969%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-4c5e4a38a6f6ec3f2a2f437aede8e43e80570be55c8436bfda7a82925a90aaa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1913405802&rft_id=info:pmid/28508826&rft_galeid=A492865969&rfr_iscdi=true |